Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.33 |
| ▸ | CYP27A1 | Q02318 | 2/20 | 0.33 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2419510 | 0.88 | MEN1 (0.31) | — | |
| SCHEMBL2423359 | 0.80 | CYP24A1 (0.31) | CYP24A1CYP27A1CRBNTHRATHRB | |
| SCHEMBL2416248 | 0.76 | HTR2A (0.32) | HTR2A | |
| SCHEMBL4857653 | 0.75 | ALDH1A1 (0.44) | — | |
| SCHEMBL2421172 | 0.74 | HTR1A (0.33) | HTR2CHTR2ADRD2HTR1ADRD4 | |
| SCHEMBL6152154 | 0.74 | DRD3 (0.32) | SGPL1HTR2CHTR2ADRD2HTR1A | |
| SCHEMBL8460075 | 0.71 | THRA (0.37) | SGPL1S1PR1THRATHRBCYP19A1 | |
| SCHEMBL4852334 | 0.71 | KDM4E (0.45) | DRD2DRD3 | |
| SCHEMBL5336349 | 0.71 | — | — | |
| SCHEMBL6137841 | 0.70 | CRBN (0.32) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432284-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20060041003-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| EP-1551820-A2 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026887-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041003-A1 | Estrogen receptor modulators | GPER1, ESR2, ESR1 | CYP24A1 319/4885CYP27A1 279/4885SGPL1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.